Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) ended Friday session in green amid volatile trading. The shares closed up +0.09 points or 1.95% at $4.70 with 2.36 million shares getting traded. Post opening the session at $4.58, the shares hit an intraday low of $4.50 and an intraday high of $4.70 and the price vacillated in this range throughout the day. The company has a market cap of $507.42 million and the numbers of outstanding shares have been calculated to be 105.90 million shares.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended Friday session in green amid volatile trading. The shares closed up +0.01 points or 0.12% at $8.07 with 2.31 million shares getting traded. Post opening the session at $8.01, the shares hit an intraday low of $7.97 and an intraday high of $8.20 and the price vacillated in this range throughout the day. The company has a market cap of $1.10 billion and the numbers of outstanding shares have been calculated to be 136.68 million shares.
Achillion Pharmaceuticals, Inc. (ACHN) on Sept. 09, 2016 announced that new interim results from a phase 2a study being conducted by Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies (Janssen), were published as part of the abstracts released for the upcoming European Association for the Study of the Liver (EASL) Special Conference, September 23 – 24, 2016, in Paris, France.
This ongoing phase 2a study was designed to confirm the required dose and treatment duration for an all-oral combination regimen containing odalasvir (ODV) and AL-335 with or without simeprevir (SMV) for durations of eight or six weeks of treatment in treatment-naïve patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.
“We are delighted by the significant progress Janssen has made in advancing the all-oral, short-duration treatment regimen of odalasvir, AL-335 and simeprevir and are impressed with the Phase 2a study results being presented. Based on these interim results, Janssen plans to advance a phase 2b program for the triple combination to further understand the potential of this 3DAA drug combination to shorten the duration of treatment for patients suffering from HCV,” commented Dr. Milind Deshpande, President and Chief Executive Officer of Achillion. “Despite recent therapeutic advances, we believe there remains a significant unmet need in addressing the global burden of hepatitis C virus in those living with the disease.”
Data included in the abstract were as of the time of submission in July 2016. Updated results, including sustained viral response 12 weeks after completion of therapy (SVR12) for all cohorts, are scheduled to be presented on Friday, September 23, 2016, in an ePoster entitled “Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection.” Interim results from cohorts 1-4, summarized in the table below, showed that the triple combination regimen was highly effective and well tolerated in non-cirrhotic patients with GT1 HCV.